BerGenBio

Report Publication Announcement • Feb 18, 2025

BerGenBio ASA: Invitation to fourth quarter 2024 results webcast

BerGenBio ASA: Invitation to fourth quarter 2024 results webcast

Bergen, Norway, 18 February 2025- BerGenBio ASA (OSE: BGBIO), a clinical-stage

biopharmaceutical company developing novel, selective AXL inhibitors for severe

unmet medical needs, will be announcing its results for the fourth quarter 2024

on Wednesday 26 February 2025.

BerGenBio's senior management team will provide a business update at 10:30 am

CET.

The presentation will webcast live. To participate in the webcast please use

this link:

https://channel.royalcast.com/landingpage/hegnarmedia/20250226_5/

The link to the live webcast and a recording of the webcast will be available at

www.bergenbio.com in the Investors/Financial Reports

section (https://www.bergenbio.com/investors/financial-reports).

The fourth quarter financial report and presentation will also be made available

on the Company's website in the Investors/Financial Reports

section (https://www.bergenbio.com/investors/financial-reports) from 7:00am CET

the same day.

-End-

Contacts

Olav Hellebø, CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Media Relations

Jan Lilleby

jl@lillebyfrisch.no

+47 90 55 16 98

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer. BerGenBio is based in Bergen, Norway with

a subsidiary in Oxford, UK.

The Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more

information, visit www.bergenbio.com.

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties, and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.